Mopidamol

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 461104

CAS#: 13665-88-8

Description: Mopidamol is a derivative of dipyridamole, is a phosphodiesterase inhibitor that has been shown previously to limit progression of malignancy in certain experimental animal models and in a pilot study in humans.

Chemical Structure

img
Mopidamol
CAS# 13665-88-8
Instruction

Theoretical Analysis

MedKoo Cat#: 461104
Name: Mopidamol
CAS#: 13665-88-8
Chemical Formula: C19H31N7O4
Exact Mass: 421.24
Molecular Weight: 421.500
Elemental Analysis: C, 54.14; H, 7.41; N, 23.26; O, 15.18

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: Mopidamol; Rapenton; RA 233; RA-233; RA233;

IUPAC/Chemical Name: 2,2',2'',2'''-((4-(piperidin-1-yl)pyrimido[5,4-d]pyrimidine-2,6-diyl)bis(azanetriyl))tetrakis(ethan-1-ol)

InChi Key: FOYWNSCCNCUEPU-UHFFFAOYSA-N

InChi Code: InChI=1S/C19H31N7O4/c27-10-6-25(7-11-28)18-20-14-15-16(22-18)17(24-4-2-1-3-5-24)23-19(21-15)26(8-12-29)9-13-30/h14,27-30H,1-13H2

SMILES Code: OCCN(CCO)c1nc2cnc(N(CCO)CCO)nc2c(N3CCCCC3)n1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >3 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.03.00

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 421.50 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Blaha H, Dierkesmann R, Feuerer W, Gatzemaier U, Geser C, Lemme J, Mall W, Ritscher R, Schneider B, Vallee D. [Adjuvant therapy of non-small cell bronchial cancer with mopidamol]. Pneumologie. 1989 Jun;43(6):299-304. German. PubMed PMID: 2547216.

2: Zacharski LR, Moritz TE, Baczek LA, Rickles FR, Edwards RL, Forman WB, Forcier RJ, Cornell CJ, Haakenson CM, Ballard HS, et al. Effect of mopidamol on survival in carcinoma of the lung and colon: final report of Veterans Administration Cooperative Study No. 188. J Natl Cancer Inst. 1988 Mar 16;80(2):90-7. PubMed PMID: 2830407.

3: Mopidamol. J Natl Cancer Inst. 1988 Jun 1;80(7):532-4. PubMed PMID: 2835491.

4: Livingston RB. Mopidamol in non-small cell lung cancer: anti-oncogene or accident? J Natl Cancer Inst. 1988 Mar 16;80(2):77-8. PubMed PMID: 2830406.

5: Trentesaux C, Jeannesson P, Carpentier Y, Kouamouo J, Jardillier JC. Effects of a new antitumor compound, mopidamol, on thymidine and 2-deoxyglucose transport in leukaemic L 1210 cells. Arzneimittelforschung. 1984;34(1):5-8. PubMed PMID: 6538421.

6: De La Cruz JP, Ortega G, Sánchez de la Cuesta F. Differential effects of the pyrimido-pyrimidine derivatives, dipyridamole and mopidamol, on platelet and vascular cyclooxygenase activity. Biochem Pharmacol. 1994 Jan 20;47(2):209-15. PubMed PMID: 8304965.

7: De La Cruz JP, Moreno A, Mérida F, García Campos J, Sánchez de la Cuesta F. The pyrimido-pyrimidine derivatives, dipyridamole, mopidamol and RA-642, prevent from retinal vascular defects in experimental diabetes mellitus. Thromb Res. 1996 Feb 1;81(3):327-37. PubMed PMID: 8928090.

8: De La Cruz JP, Villalobos MA, Palacios R, Smith-Agreda JM, Sánchez de la Cuesta F. In vitro effect of mopidamol on platelet-subendothelium interaction. Thromb Res. 1995 Jan 1;77(1):97-103. PubMed PMID: 7701482.

9: de la Cruz JP, Moreno A, Mérida F, García-Campos J, Sánchez de la Cuesta F. The pyrimido-pyrimidine derivatives, dipyridamole and RA-642, reduce opacification of crystalline lens in diabetic rats. Pharmacol Toxicol. 1994 Nov;75(5):250-4. PubMed PMID: 7870694.

10: De la Cruz JP, Olveira C, Gonzalez-Correa JA, Benítez A, Sánchez de la Cuesta F. Inhibition of ferrous-induced lipid peroxidation by dipyridamole, RA-642 and mopidamol in human lung tissue. Gen Pharmacol. 1996 Jul;27(5):855-9. PubMed PMID: 8842690.

11: Gastpar H. [Modification of metastasis formation by inhibition of platelet aggregation. Experimental and clinical results]. Laryngol Rhinol Otol (Stuttg). 1983 Dec;62(12):578-85. Review. German. PubMed PMID: 6369051.

12: Li XT, Hellmann K. Antitumor effect of RA233 alone and combined with radiotherapy. Clin Exp Metastasis. 1983 Apr-Jun;1(2):181-90. PubMed PMID: 6546197.

13: Stackpole CW, Fornabaio DM, Alterman AL. Failure of orally administered RA233 to influence B16 melanoma growth or metastasis. Clin Exp Metastasis. 1987 Apr-Jun;5(2):165-80. PubMed PMID: 3594974.

14: Bamford CH, Middleton IP, Al-Lamee KG. Polymeric inhibitors of platelet aggregation. II. Copolymers of dipyridamole and related drugs with N-vinylpyrrolidone. Biochim Biophys Acta. 1987 Apr 16;924(1):38-44. PubMed PMID: 3828396.

15: Gastpar H. Platelet aggregation inhibitors and cancer metastasis. Ann Chir Gynaecol. 1982;71(3):142-50. Review. PubMed PMID: 6287902.

16: Lichtner RB, Hutchinson G, Wedderburn N, Hellmann K. Antiplatelet pyrimido-pyrimidines and metastasis. Cancer Treat Rev. 1985 Dec;12(4):221-34. Review. PubMed PMID: 3009013.

17: Ambrus JL, Bannerman RM, Sills RH, Meky N, Sharma S, Stadler S, Gastpar H, Marton J, Melewski DJ. Studies on the vasoocclusive crisis of sickle cell disease. III. In vitro and in vivo effect of the pyrimido-pyrimidine derivative, RA-233: studies on its mechanism of action. J Med. 1987;18(3-4):165-98. PubMed PMID: 3480932.

18: Meky N. Effect of RA-233 on erythrocytes from patients with eczema. J Med. 1988;19(1):33-45. PubMed PMID: 3221142.

19: Bellido I, de la Cruz JP, Sánchez de la Cuesta F. The pyrimido-pyrimidine derivative RA-642: a potent inhibitor of ferrous-induced lipid peroxidation in cell membranes. Methods Find Exp Clin Pharmacol. 1991 Jul-Aug;13(6):371-5. PubMed PMID: 1881198.

20: Bonta IL, Parnham MJ, Adolfs MJ. Mimickry of anti-granuloma effect of prostaglandin E by dibutyryl cyclic-AMP and some phosphodiesterase inhibitors. Agents Actions Suppl. 1979;(4):278-85. PubMed PMID: 91315.